Compare SMHI & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMHI | IPHA |
|---|---|---|
| Founded | 1989 | 1999 |
| Country | United States | France |
| Employees | N/A | 163 |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 212.7M | 189.5M |
| IPO Year | 2016 | N/A |
| Metric | SMHI | IPHA |
|---|---|---|
| Price | $7.55 | $1.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.75 |
| AVG Volume (30 Days) | ★ 130.2K | 11.7K |
| Earning Date | 04-29-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.41 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $173,783,000.00 | N/A |
| Revenue This Year | $1.21 | $180.36 |
| Revenue Next Year | $9.31 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.70 | $1.18 |
| 52 Week High | $8.17 | $2.63 |
| Indicator | SMHI | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 53.20 | 52.34 |
| Support Level | $6.92 | $1.73 |
| Resistance Level | $7.69 | $1.98 |
| Average True Range (ATR) | 0.51 | 0.08 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 68.95 | 36.15 |
Seacor Marine Holdings Inc provides marine and support transportation services to offshore energy facilities globally. The company operates and manages a diverse fleet of offshore support vessels that (i) deliver cargo and personnel to offshore installations, including offshore wind farms, (ii) assist offshore operations for production and storage facilities, (iii) provide construction, well work-over, offshore wind farm installation and decommissioning support and (iv) carry and launch equipment used underwater in drilling and well installation, maintenance, inspection and repair. Its geographical segment includes the United States (Gulf of Mexico), Africa and Europe, Middle East and Asia, and Latin America, with the majority of revenue deriving from the Africa and Europe segment.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.